Ellagic acid inhibits migration and invasion by prostate cancer cell lines

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 5, 2013, Pages 2859-2863

  Pitchakarn, Pornsiri ^a,b   Chewonarin, Teera ^a,b   Ogawa, Kumiko ^b,c   Suzuki, Shugo ^b   Asamoto, Makoto ^b   Takahashi, Satoru ^b   Shirai, Tomoyuki ^b   Limtrakul, Pornngarm ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b NAGOYA CITY UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Cancer; Ellagic acid; Invasion; Metastasis; Migration

Indexed keywords

COLLAGENASE; ELLAGIC ACID; GELATINASE; GELATINASE A; GELATINASE B; MMP2 PROTEIN, HUMAN; MMP2 PROTEIN, RAT; MMP9 PROTEIN, HUMAN; MMP9 PROTEIN, RAT; PLANT EXTRACT;

ANIMAL; APOPTOSIS; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; FISCHER 344 RAT; HUMAN; LYTHRACEAE; MALE; PATHOLOGY; PROSTATE TUMOR; RAT; SECRETION (PROCESS); TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLLAGENASES; ELLAGIC ACID; GELATINASES; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; PLANT EXTRACTS; PROSTATIC NEOPLASMS; PUNICACEAE; RATS; RATS, INBRED F344;

EID: 84880377581     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.5.2859     Document Type: Article

References (38)

1. Azzam HS, Thompson EW (1992). Collagen-induced activation of the M(r) 72,000 type IV collagenase in normal and malignant human fibroblastoid cells. Cancer Res, 52, 4540-4.
2. Bell C, Hawthorne S (2008). Ellagic acid, pomegranate and prostate cancer -- a mini review. J Pharm Pharmacol, 60, 139-44.
3. Bianco FJ Jr, Gervasi DC, Tiguert R, et al (1998). Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. Clin Cancer Res, 4, 3011-6.
4. Braun-Falco M, Holtmann C, Lordick F, et al (2006). Follicular drug reaction from cetuximab: a common side effect in the treatment of metastatic colon carcinoma. Hautarzt, 57, 701-4.
5. Castonguay AGHU, Perchellet EM (1997). Antitumorigenic and antipromoting activities of ellagic acid, ellagitannins and oligometric anthocyanin and procyanidin. Int J Oncol, 10, 367-73.
6. Cockett MI, Murphy G, Birch ML, et al (1998). Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp, 63, 295-313.
7. Fernandez-Patron C, Radomski MW, Davidge ST (1999). Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res, 85, 906-11.
8. Fidler IJ, Kripke ML (1977). Metastasis results from preexisting variant cells within a malignant tumor. Science, 197, 893-5.
9. Giancotti FG, Ruoslahti E (1999). Integrin signaling. Science, 285, 1028-32.
10. Gilles C, Polette M, Seiki M, et al (1997). Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. Lab Invest, 76, 651-60.
11. Gronberg H (2003). Prostate cancer epidemiology. Lancet, 361, 859-64.
12. Hamasaki K, Kogure K, Ohwada K (1996). A biological method for the quantitative measurement of tetrodotoxin (TTX): tissue culture bioassay in combination with a water-soluble tetrazolium salt. Toxicon, 34, 490-5.
13. Han DH, Lee MJ, Kim JH (2006). Antioxidant and apoptosisinducing activities of ellagic acid. Anticancer Res, 26, 3601-6.
14. Jemal A, Siegel R, Ward E, et al (2008). Cancer statistics, 2008. CA Cancer J Clin, 58, 71-96.
15. Khanduja KL, Avti PK, Kumar S, et al (2006). Anti-apoptotic activity of caffeic acid, ellagic acid and ferulic acid in normal human peripheral blood mononuclear cells: a Bcl- 2 independent mechanism. Biochim Biophys Acta, 1760, 283-9.
16. Lansky EP, Harrison G, Froom P, et al (2005). Pomegranate (Punica granatum) pure chemicals show possible synergistic inhibition of human PC-3 prostate cancer cell invasion across Matrigel. Invest New Drugs, 23, 121-2.
17. Larrosa M, Tomas-Barberan FA, Espin JC (2006). The dietary hydrolysable tannin punicalagin releases ellagic acid that induces apoptosis in human colon adenocarcinoma Caco-2 cells by using the mitochondrial pathway. J Nutr Biochem, 17, 611-25.
18. Lin SS, Lai KC, Hsu SC, et al (2009). Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and vascular endothelial growth gactor (VEGF). Cancer Lett, 285, 127-33.
19. Liotta LA, Rao CN, Wewer UM (1986). Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem, 55, 1037-57.
20. Li TM, Chen GW, Su CC, et al (2005). Ellagic acid induced p53/p21 expression, G1 arrest and apoptosis in human bladder cancer T24 cells. Anticancer Res, 25, 971-9.
21. Longtin R (2003). The pomegranate: nature's power fruit?. J Natl Cancer Inst, 95, 346-8.
22. Mukhtar H, Das M, Khan WA, et al (1988). Exceptional activity of tannic acid among naturally occurring plant phenols in protecting against 7,12-dimethylbenz(a) anthracene-, benzo(a)pyrene-, 3-methylcholanthrene-, and N-methyl-N-nitrosourea-induced skin tumorigenesis in mice. Cancer Res, 48, 2361-5.
23. Nagase H, Woessner JF, Jr. (1999). Matrix metalloproteinases. J Biol Chem, 274, 21491-4.
24. Nakanishi H TS, Kato K, Shimizu S, et al (1996). Establishment and characterization of three androgen-independent, metastatic carcinoma cell lines from 3,2'-dimethyl-4-aminobiphenyl-induced prostatic tumors in F344 rats. Jpn J Cancer Res, 87, 1218-26.
25. Narayanan BA, Geoffroy O, Willingham MC, et al (1999). p53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Lett, 136, 215-21.
26. Papathoma AS, Zoumpourlis V, Balmain A, et al (2001). Role of matrix metalloproteinase-9 in progression of mouse skin carcinogenesis. Mol Carcinog, 31, 74-82.
27. Pitchakarn P, Ogawa K, Suzuki S, et al (2010). Momordica charantia leaf extract suppresses rat prostate cancer progression in vitro and in vivo. Cancer Sci, 101, 2234-40.
28. Seeram NP, Adams LS, Henning SM, et al (2005). In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem, 16, 360-7.
29. Seeram NP, Henning SM, Zhang Y, et al (2006). Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr, 136, 2481-5.
30. Seeram NP, Aronson WJ, Zhang Y, et al (2007). Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem, 55, 7732-7.
31. Stetler-Stevenson WG (1990). Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev, 9, 289-303.
32. Stoner GD, Gupta A (2001). Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis, 22, 1737-46.
33. Strati A, Papoutsi Z, Lianidou E, et al (2009). Effect of ellagic acid on the expression of human telomerase reverse transcriptase (hTERT) alpha+beta+ transcript in estrogen receptor-positive MCF-7 breast cancer cells. Clin Biochem, 42, 1358-62.
34. Thresiamma KC, Kuttan R (1996). Inhibition of liver fibrosis by ellagic acid. Indian J Physiol Pharmacol, 40, 363-6.
35. Wang M, Wang T, Liu S, et al (2003). The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol, 20, 65-72.
36. Westermarck J, Kahari VM (1999). Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J, 13, 781-92.
37. Yodkeeree S, Garbisa S, Limtrakul P (2008). Tetrahydrocurcumin inhibits HT1080 cell migration and invasion via downregulation of MMPs and uPA. Acta Pharmacol Sin, 29, 853-60.
38. Zeng ZS, Cohen AM, Guillem JG (1999). Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis, 20, 749-55.